CereMark Pharma
  • Home
  • Pipeline
    • Overview
    • F-18 Flornaptitril
  • Leadership Team
    • Management Team
    • Board of Directors
    • Emeritus Founders Advisory Board
    • Medical And Science Advisory Board (MSAB)
  • News
  • Contact Us
Select Page

CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration  

by Brian Fitzgerald | Jul 10, 2025 | News

F-18 Flornaptitril was designed to simultaneously detect tau aggregates and beta-amyloid plaques within a single PET scan   WHEELING, WV – July 9, 2025 – CereMark Pharma (CereMark), a clinical-stage radiopharmaceutical company focused on the detection, diagnosis...

Recent Posts

  • CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration  
  • CereMark Pharma and Hall of Fame Health Team Up to Investigate the Clinical Progression of Neurodegeneration in Athletes and Soldiers
  • CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril
  • CereMark Pharma Announces New Patents on Selective Imaging Agent of Alzheimer’s Disease, Chronic Traumatic Encephalopathy and Other Neurodegenerative Diseases
  • Patent Awarded for PET Radiopharmaceutical for Neurodegeneration Imaging

Recent Comments

  1. A WordPress Commenter on Hello world!

Contact Us

  • Follow
  • Follow

Our Partners